A director at Prudential bought 84,016 shares at 738p and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
Prudential’s 1Q24 ANP/NBP growth came in below expectations with 7%/11% yoy growth respectively, dragged by muted performance from China and Hong Kong on a high base, but offset by strong growth in Malaysia and the other markets segment. NBP margin ex-economic impact improved to 50% due to favourable product mix in the Greater China segment. The company will provide an update on capital management plans during its 1H24 results. Maintain BUY. Target price: HK$134.00.
KEY HIGHLIGHTS Economics PMI Manufacturing PMI came in better than expected at 50.4% (-0.4ppt) and stayed in the expansionary zone for the second month. It was mainly supported by production and new orders as employment remained a drag, dropping 0.1ppt to 48.0%. Non-manufacturing hit a three-month low of 51.2%, dragged by moderation in new orders and business expectations. We expect policy support to continue and the July Politburo may see new measures being rolled out. Sector Aviation T...
New York , April 18, 2024 – Moody's Ratings (Moody's) has assigned ratings to Prudential Financial, Inc.'s (NYSE: PRU) (PFI or Prudential) shelf registration filed in March 1, 2024, including (P)A3 to the senior unsecured shelf, (P)Baa1 to the subordinated shelf, (P)Baa2 to the preferred shelf and (...
We believe the recent regulatory action has limited impact on AIA and Prudential due to the small quantum of new business contribution from the involved brokers. We continue to expect regional insurers to deliver at least 20% yoy new business growth in 1Q24. However, high interest rates and market uncertainty could continue to weigh on their valuations in the near term. Any upside surprise in 1Q24 new business or favourable updates in shareholder returns could turn sentiment around. Maintain MAR...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024 CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, May 9th. Management will host a conference call at 5:00 p.m. Eastern Time ...
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company’s motion to dismiss all claims asserted. “We are very pleased with the Court's dec...
Despite APE sales meeting our expectation, Prudential’s 2023 NBP beat our forecast by 9.2%, mainly driven by better-than-expected margin performances across key markets due to favourable shifts in its product and channel mix. With sales growth momentum continuing into 2M24 and a more encouraging margin outlook, we foresee Prudential delivering strong NBP growth in 2024. Therefore, we revise our NBP forecasts upward and increase target price to HK$142.00. Maintain BUY.
KEY HIGHLIGHTS Results Anhui Conch Cement (914 HK/BUY/HK$17.20/Target: HK$21.00) 2023: In line; all set to expand market share. CSPC Pharmaceutical Group (1093 HK/BUY/HK$6.41/Target: HK$7.80) 2023: Results in line; expects double-digit revenue and earnings growth in 2024. Geely Auto (175 HK/BUY/HK$8.83/Target: HK$11.00) 2023: Results beat on margins again; upgrade to BUY. Raise target price from HK$6.50 to HK$11.00. Innovent Biologics (1801 HK/BUY/HK$39.35/Target: HK$60.00) 2023: Results ...
GREATER CHINA Results Geely Auto (175 HK/BUY/HK$8.83/Target: HK$11.00): 2023: Results beat on margins again; upgrade to BUY. Raise target price from HK$6.50 to HK$11.00. Innovent Biologics (1801 HK/BUY/HK$39.35/Target: HK$60.00): 2023: Results beat; well positioned for sustainable growth in 2024. Kuaishou (1024 HK/BUY/HK$52.25/Target: HK$85.00): 4Q23: Resilient earnings beat; strong ad monetisation momentum continues. Li Ning (2331 HK/HOLD/HK$21.45/Target: HK$19.60): 2023: Results miss; remain c...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.